This was demonstrated by increased IFN-γ, interleukin (IL)-12 and nitric oxide synthase (NOS)-2 mRNA levels and reduced mycobacterial burden in 5-LOX-deficient mice.19 At present, no trials evaluating 5-LOX inhibitors as HDT complementing standard TB treatment are registered on the clinicaltrials.gov resource database. The gene discussed is ALOX5; the disease is tuberculosis.